

Poster presentations ESMO 2025

I had the opportunity to attend the ESMO 2025 Congress, which took place in Berlin, Germany, from October 17th to 21st. These four days were dedicated to various sessions covering a broad range of oncology topics, including an inspiring session on sex differences in the pharmacology of oncolytic agents. This was particularly relevant to one of my poster presentations, which focused on sex-related effects of alectinib in patients with ALK-positive non-small cell lung cancer. The discussions during and after this session provided valuable insights into pharmacokinetic and pharmacodynamic mechanisms that may underlie the observed differences between males and females.

My second poster presentation focused on a food–drug interaction study of DO-2, a novel MET inhibitor currently in phase 1 clinical development. The poster highlighted how pharmacokinetic profiles can be optimized through drug–food interactions, representing an important step in early-phase oncology trials.

Overall, attending ESMO 2025 was an inspiring and rewarding experience that provided an great opportunity to present my work, exchange ideas, and connect with fellow researchers from around the world.

